Browsing Tag
JNJ-5939
1 post
Johnson & Johnson discontinues JNJ-5939 after DUPLEX-AD trial misses efficacy threshold in atopic dermatitis
Johnson & Johnson has discontinued JNJ-5939 in atopic dermatitis after interim trial results fell short of efficacy benchmarks. Find out what this means for the pipeline.